sinc
first
human
infect
novel
avian
influenza
viru
report
march
total
confirm
case
death
china
report
decemb
rel
silent
period
juli
octob
four
case
one
death
report
viru
reemerg
sinc
novemb
result
second
outbreak
novel
influenza
viru
bind
avian
alpha
sialic
acid
human
alpha
sialic
acid
also
contain
humanadapt
amino
acid
adapt
may
explain
viru
caus
outbreak
human
patient
infect
viru
typic
show
symptom
fever
cough
opac
consolid
chest
radiographi
sever
case
progress
acut
respiratori
distress
syndrom
ard
multiorgan
although
lethal
influenza
compar
lower
highli
pathogen
viral
infect
much
higher
pandem
influenza
reach
approxim
furthermor
highpathogen
marker
humanadapt
influenza
viru
amino
acid
substitut
gene
haemagglutinin
ha
gene
identifi
recent
isol
suggest
viru
might
becom
virul
human
thu
pandem
potenti
lethal
influenza
rais
public
concern
although
earli
treatment
oseltamivir
peramivir
drugresist
mutant
viru
found
soon
patient
receiv
antiinfluenza
candid
inactiv
viru
vaccin
viruslik
particl
vlp
vaccin
viru
howev
use
inactiv
viru
vaccin
vlp
may
provid
protect
mutat
reassort
influenza
viru
fact
surveil
studi
suggest
novel
influenza
viru
new
reassort
sever
influenza
virus
includ
therefor
develop
univers
influenza
vaccin
attract
goal
scientist
around
world
regard
ectodomain
matrix
protein
influenza
virus
may
promis
target
develop
univers
influenza
vaccin
rel
conserv
differ
subtyp
influenza
anim
experi
demonstr
vaccin
provid
crossprotect
infect
differ
subtyp
influenza
viru
antibodi
could
react
differ
subtyp
influenza
viru
variou
vaccin
develop
recombin
protein
plasmid
dna
peptid
previou
studi
construct
tetramer
vaccin
candid
demonstr
could
provid
crossprotect
lethal
infect
differ
clade
pandem
studi
extend
investig
evalu
crossprotect
lethal
infect
novel
avian
influenza
viru
mice
six
eightweekold
femal
balbc
mice
provid
laboratori
anim
unit
univers
hong
kong
mice
maintain
cage
provid
steril
food
water
anim
facil
anim
studi
approv
committe
use
live
anim
teach
research
culatr
univers
hong
kong
tetrabranch
peptid
encod
ahong
figur
synthes
gl
biochem
ltd
shanghai
china
mouseadapt
viru
inocul
specif
pathogenfre
spf
egg
allanto
fluid
collect
threeday
incub
allanto
fluid
aliquot
store
use
viru
titer
detect
tissu
cultur
infect
dose
assay
lethal
dose
determin
challeng
balbc
mice
serial
dilut
viru
describ
experi
involv
viru
perform
biosafeti
level
facil
describ
two
group
balbc
mice
micegroup
subcutan
sc
vaccin
tetram
peptid
premix
respect
freund
adjuv
fa
sigma
st
loui
usa
sigma
adjuv
system
sa
sigma
st
loui
usa
describ
three
group
mice
micegroup
sc
inject
fa
sa
phosphatebuff
salin
pb
alon
neg
control
briefli
mice
primaryimmun
premix
complet
fa
sa
boost
peptid
incomplet
fa
sa
twice
threeweek
interv
mice
sera
collect
day
prior
vaccin
day
second
booster
vaccin
detect
specif
antibodi
ten
day
last
vaccin
mice
intranas
inocul
mouseadapt
strain
anesthet
ketamin
xylazin
challeng
mice
observ
day
till
death
lung
tissu
collect
micegroup
day
postchalleng
virolog
patholog
investig
titer
antibodi
detect
elisa
describ
briefli
microtit
plate
sigma
st
loui
usa
coat
either
gl
biochem
ltd
shanghai
china
concentr
incub
overnight
coat
plate
block
bovin
serum
albumin
pb
h
room
temperatur
rt
serial
dilut
sera
ad
plate
incub
rt
h
horseradish
peroxideconjug
goat
antimous
immunoglobulin
g
antibodi
dako
glostrup
denmark
ad
plate
incub
rt
h
substrat
life
technolog
carlsbad
ca
usa
ad
plate
incub
rt
h
reaction
stop
ad
result
measur
absorb
nm
use
elisa
reader
beckman
coulter
brea
ca
usa
viru
titer
detect
assay
describ
briefli
infect
allanto
fluid
mous
lung
homogen
serial
dilut
minimum
essenti
medium
invitrogen
waltham
usa
contain
cocktail
antibiot
dilut
sampl
ad
pbsprewash
canin
kidney
cell
monolay
plate
cell
cultur
incub
h
supernat
replac
fresh
minimum
essenti
medium
contain
cocktail
antibiot
cytopath
effect
appear
infect
canin
kidney
cell
observ
daili
record
thirdday
postinfect
viral
rna
copi
mous
lung
homogen
measur
quantit
reversetranscript
polymeras
chain
reaction
qrtpcr
describ
briefli
viral
rna
mous
lung
homogen
extract
use
rneasi
mini
kit
qiagen
valencia
ca
usa
extract
viral
rna
reversetranscrib
cdna
use
superscript
ii
invitrogen
waltham
usa
primer
agc
aaa
agc
viral
rna
copi
number
sampl
determin
use
lightcycl
roch
appli
scienc
penzberg
germani
sybr
green
master
roch
appli
scienc
penzberg
germani
primer
specif
influenza
viral
gene
forward
primer
cta
acc
gag
gtc
gaa
revers
primer
att
ttg
gac
aaa
kcg
tct
use
qrtpcr
assay
lung
tissu
collect
infect
mice
fix
formalin
fix
tissu
embed
paraffin
wax
sampl
cut
section
section
mount
slide
examin
h
e
stain
describ
structur
ahong
predict
use
onlin
softwar
pepfold
http
bioservrpbsunivparisdiderotfrpepfold
describ
predict
model
highest
score
chosen
discuss
purpos
result
present
mean
standard
deviat
sd
statist
signific
differ
vaccin
group
calcul
student
ttest
analysi
use
statist
packag
social
scienc
intern
busi
machin
corpor
armonk
ny
usa
statist
softwar
pvalu
less
consid
signific
shown
figur
differ
five
amino
acid
observ
sequenc
examin
whether
variat
would
affect
reaction
antibodi
induc
vaccin
test
antibodi
titer
serum
sampl
collect
mice
use
elisa
plate
coat
respect
titer
immunoglobulin
g
antibodi
specif
figur
figur
gradual
increas
mous
serum
sampl
collect
vaccin
reach
high
level
day
last
booster
vaccin
contrast
antibodi
undetect
serum
sampl
collect
mice
vaccin
fa
sa
pb
alon
adjuv
effect
sa
seem
better
fa
plu
sa
induc
higher
level
antibodi
respons
importantli
antibodi
titer
specif
similar
p
result
indic
vaccin
induc
high
level
antibodi
effect
crossreact
although
differ
approxim
amino
acid
identifi
sequenc
furthermor
anoth
viru
strain
ahong
nonreact
induc
includ
neg
control
elisa
experi
shown
figur
titer
crossreact
antibodi
approxim
log
lower
p
indic
vaccin
induc
suffici
antibodi
toward
evalu
whether
vaccin
could
provid
effect
crossprotect
lethal
infect
viru
mice
challeng
mouseadapt
viru
shown
figur
vaccin
either
fa
sa
could
protect
mice
lethal
challeng
viru
protect
effect
similar
result
experi
use
lethal
challeng
homogen
contrast
surviv
rate
mice
vaccin
sa
pb
interestingli
mice
vaccin
fa
also
surviv
lethal
challeng
surviv
rate
surviv
rate
mice
significantli
higher
mice
vaccin
fa
sa
pb
p
result
show
vaccin
could
provid
satisfactori
crossprotect
lethal
infect
novel
viru
examin
whether
vaccin
could
inhibit
viral
infect
tissu
damag
lung
mice
challeng
lethal
dose
viru
six
mice
per
group
sacrif
day
postchalleng
lung
collect
detect
viral
load
tissu
damag
detect
assay
qrtpcr
viru
titer
figur
viral
rna
copi
figur
lung
mice
vaccin
significantli
reduc
approxim
log
lower
mice
vaccin
fa
sa
pb
p
consist
result
h
e
stain
show
lung
patholog
mice
vaccin
less
sever
mice
vaccin
adjuv
pb
sever
damag
lung
tissu
observ
adjuv
pbsvaccin
mice
includ
damag
bronchial
epithelium
denatur
pneumocyt
neutrophil
mononuclear
cell
mark
infiltr
lymphocyt
fuse
alveoli
wall
focal
hemorrhag
figur
analyz
monom
sequenc
use
pepfold
compar
structur
differ
predict
model
ahong
nonreact
induc
crossreact
includ
analysi
shown
figur
four
fold
hairpin
shape
ushap
region
expos
structur
differ
four
peptid
might
due
properti
substitut
amino
acid
might
affect
antigen
site
access
control
potenti
new
influenza
pandem
best
measur
may
develop
univers
influenza
vaccin
exist
vaccin
provid
effect
crossprotect
mutat
reassort
novel
influenza
viru
current
effort
develop
univers
vaccin
includ
develop
vaccin
ha
stem
vaccin
vaccin
candid
provid
crossprotect
infect
differ
subtyp
influenza
previou
studi
show
tetramer
peptid
vaccin
exhibit
promis
protect
lethal
challeng
differ
clade
viru
subtyp
influenza
studi
demonstr
tetramer
peptid
vaccin
could
also
offer
potent
protect
infect
novel
influenza
viru
caus
first
outbreak
march
june
second
outbreak
novemb
decemb
china
result
show
tetramer
peptid
vaccin
togeth
either
fa
sa
induc
high
antibodi
respons
abl
effect
crossreact
figur
vaccin
thu
protect
mice
lethal
challeng
viru
figur
surviv
rate
mice
lethal
challeng
mice
lethal
consist
viral
load
lung
damag
mice
much
lower
less
sever
adjuv
pbsinject
mice
figur
although
tcell
respons
induc
vaccin
report
previous
protect
vaccin
mainli
attribut
induc
antibodi
similarli
result
show
crossprotect
vaccin
directli
relat
level
crossreact
antibodi
toward
challeng
virus
unlik
vaccin
inactiv
virus
hasubunit
vaccin
vlp
vaccin
may
provid
complet
protect
infect
homogen
virus
poor
crossprotect
infect
heterogen
virus
result
illustr
tetramer
peptid
vaccin
provid
satisfactori
crossprotect
infect
novel
influenza
viru
newli
emerg
human
amino
acid
mutat
posit
reduc
monoclon
antibodi
bind
wherea
viru
mutant
posit
escap
protect
moreov
peptid
variant
posit
significantli
reduc
reactiv
antibodybind
find
indic
although
rel
conserv
among
differ
subtyp
influenza
viru
amino
acid
mutat
certain
posit
could
inde
affect
efficaci
vaccin
notabl
five
amino
acid
differ
posit
account
approxim
total
amino
acid
figur
howev
amino
acid
variat
abolish
efficaci
vaccin
protect
lethal
challeng
viru
figur
affect
despit
fact
amino
acid
variat
includ
mutat
posit
report
affect
antibodi
examin
amino
acid
variat
may
affect
structur
peptid
structur
analyz
use
onlin
softwar
pepfold
figur
structur
show
middl
region
similarli
fold
open
structur
although
five
amino
acid
differ
two
sequenc
figur
although
one
amino
acid
differ
structur
show
rel
open
structur
figur
howev
contain
amino
acid
variat
posit
figur
low
crossreact
antibodi
figur
region
fold
hairpin
structur
accord
predict
model
amino
acid
arginin
amino
acid
tryptophan
structur
bulki
locat
top
hairpin
may
provid
steric
hindranc
block
access
lower
region
structur
structur
may
limit
antibodybind
abil
antigen
process
immun
system
contrast
arginin
tryptophan
three
structur
orient
way
would
block
lower
access
observ
may
explain
vaccineinduc
antibodi
could
still
react
contain
variat
posit
could
react
contain
amino
acid
variat
posit
structur
compat
slight
protect
surviv
observ
mice
vaccin
fa
alon
figur
similar
phenomenon
also
report
studi
vaccin
fa
alon
provid
slight
protect
surviv
lethal
challeng
enteroviru
group
streptococcu
possibl
explan
adjuv
alon
may
induc
innat
immun
respons
provid
certain
level
protect
viral
nevertheless
surviv
rate
mice
vaccin
plu
fa
significantli
higher
mice
vaccin
fa
alon
p
indic
adjuv
provid
key
protect
lethal
challeng
viru
summari
studi
illustr
may
provid
potent
crossprotect
lethal
challeng
novel
avian
influenza
viru
even
though
approxim
amino
acid
differ
exist
result
suggest
tetramer
peptid
may
provid
broad
spectrum
crossprotect
infect
heterogen
influenza
virus
tetramer
peptid
may
promis
candid
develop
univers
vaccin
improv
vaccin
protect
vaccin
may
use
togeth
inactiv
viru
hasubunit
andor
type
vaccin
complet
protect
report
combin
use
vaccin
inactiv
viru
